Project Grant R41OD018403

Federal Project Grant Award Summary AVM Biotechnology, Inc. received a $992,425 Project Grant awarded on September 8, 2025, by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to develop AVM0703, a novel immunomodulatory bridging therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients. The project, which extends through August 31, 2027, focuses on advancing a proprietary high-concentration dexamethasone sodium phosphate...

Federal Grant Award Summary Sollus Therapeutics, Inc. received a $322,576 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective July 1, 2026 through June 30, 2027 to develop a modular, high-throughput screening platform for optimizing Chimeric Antigen Receptor (CAR) designs. The platform will enable systematic evaluation of CAR domain variants—including hinge, transmembrane, and signaling domains—across multiple antigens and disease...

This $683,472 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Cincinnati to develop a novel targeted therapy for acute myeloid leukemia (AML). The key objectives are to therapeutically target the DHODH enzyme to induce AML cell differentiation, activate the immune system, and induce ferroptosis-mediated cell death. This approach aims to better differentiate AML cells from normal hematopoietic stem cells and enhance...

Federal Grant Award Summary Blood Cell Technologies LLC received a $400,000 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded September 1, 2025, with completion targeted for August 31, 2026. This Fast-Track Small Business Innovation Research (SBIR) award supports the development of second-generation biliverdin IXB reductase (BLVRB) inhibitors to treat chemotherapy-induced thrombocytopenia (CIT), a dose-limiting toxicity...

Federal Grant Award Summary Cytoagents Inc. received a $1.31 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 22, 2025, with completion targeted for August 31, 2027. The award supports the development of CTO1681, an orally available pharmaceutical compound designed to prevent and mitigate cytokine release syndrome (CRS) in multiple myeloma patients undergoing chimeric antigen receptor (CAR) T-cell therapy....

Federal Grant Award Summary Award: Project Grant | Funding Agency: National Center for Advancing Translational Sciences (NCATS) | Program: NCATS (CFDA 93.350) | Awardee: Simplusdx, Inc. | Amount: $306,299 | Award Date: July 1, 2025 | Performance Period: July 1, 2025 – June 30, 2026 Simplusdx, Inc. will develop and validate a rapid point-of-care testing platform for therapeutic drug monitoring of tacrolimus, a critical immunosuppressive medication used in organ transplantation. The project adapts...

Federal Project Grant Award Summary Cellchorus Inc. received a $399,625 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 1, 2025, through August 31, 2027. The award supports the development of functional signatures for post-infusion Chimeric Antigen Receptor (CAR) T cells to enable early identification of patient response in relapsed/refractory large B cell lymphoma (R/RLBCL) cases. Cellchorus will leverage...

Federal Grant Award Summary Nuvox Pharma, L.L.C. received a $1.84 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded on September 22, 2025, with an ultimate completion date of August 31, 2027. The award supports the development and validation of liquid biopsy biomarkers as a diagnostic tool for glioblastoma (GBM) patients undergoing chemoradiation therapy combined with dodecafluoropentane emulsion (DDFPE), an...

Federal Project Grant Summary Beth Israel Deaconess Medical Center, Inc. received a $818,625 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2030. The award funds a randomized controlled trial evaluating cardioprotective strategies in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with pre-existing cardiomyopathy or prior anthracycline exposure. The primary...

Federal Grant Award Summary Persistence Therapeutics, Inc. received a $629,370 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on September 22, 2025, with an ultimate completion date of August 31, 2026. The award funds development and testing of SYNTHNODE, an innovative implantable device designed to overcome critical manufacturing and efficacy limitations in chimeric antigen receptor (CAR) T cell therapy. The dime-sized...